ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Two New Section Chiefs Named In NCI Research Contracts Branch; S. 988 Markup Set For April 25

April 18, 1980

NCI Programs: Genetic Variations Discovered, Added to NCI Database

June 11, 1999

NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.

April 20, 2007

NCI-Approved Clinical Trials

January 26, 2007

New Drug Approval: Groups Urge FDA To Move Quickly On Herceptin Approval

September 18, 1998

Trastuzumab Increases Risks Of Congestive Heart Failure

August 31, 2012